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Abstract
Background: Candidate genes of psychological importance include 5HT2A, 5HT2C, and COMT, implicated in the serotonin,
noradrenaline and dopamine pathways, which also may be involved in regulation of energy balance. We investigated the
associations of single nucleotide polymorphisms (SNPs) of these genes with obesity and metabolic traits.
Methodology/Principal Findings: In a population of 166 200 young men examined at the draft boards, obese men (n=726,
BMI$31.0 kg/m
2) and a randomly selected group (n=831) were re-examined at two surveys at mean ages 46 and 49 years
(S-46, S-49). Anthropometric, physiological and biochemical measures were available. Logistic regression analyses were used
to assess age-adjusted odds ratios. No significant associations were observed of 5HT2A rs6311, 5HT2C rs3813929 and COMT
rs4680 with obesity, except that COMT rs4680 GG-genotype was associated with fat-BMI (OR=1.08, CI=1.01–1.16). The SNPs
were associated with a number of physiological variables; most importantly 5HT2C rs3813929 T-allele was associated with
glucose (OR=4.56, CI=1.13–18.4) and acute insulin response (OR=0.65, CI=0.44–0.94) in S-49. COMT rs4680 GG-genotype
was associated with glucose (OR=1.04, CI=1.00–1.09). Except for an association between 5HT2A rs6311 and total-
cholesterol at both surveys, significant in S-46 (OR=2.66, CI=1.11–6.40), no significant associations were observed for the
other phenotypes. Significant associations were obtained when combined genotype of 5HT2C rs3813929 and COMT rs4680
were examined in relation to BMI (OR=1.12, CI=1.03–1.21), fat-BMI (OR=1.22, CI=1.08–1.38), waist (OR=1.13, CI=1.04–
1.22), and cholesterol (OR=5.60, CI=0.99–31.4). Analyses of impaired glucose tolerance (IGT) and type 2 diabetes (T2D)
revealed, a 12.3% increased frequency of 5HT2C rs3813929 T-allele and an 11.6% increased frequency of COMT rs4680 GG-
genotype in individuals with IGT or T2D (x
2, p=0.05 and p=0.06, respectively). Examination of the combined genotypes of
5HT2C and COMT showed a 34.0% increased frequency of IGT or T2D (x
2, p=0.01).
Conclusions: The findings lend further support to the involvement of serotonin, noradrenaline and dopamine pathways on
obesity and glucose homeostasis, in particular when combined genotype associations are explored.
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Introduction
The fundamental causes of obesity relate to a complex interplay
between environmental exposure, health behaviour and inherited
components [1]. Obesity and body fat distribution are important
determinant of glucose homeostasis [2,3] with insulin resistance as
the maincontributor tothe deleterious consequences of obesity,such
as development of metabolic diseases, IGT, T2D and eventually
cardiovascular disease [4]. Deeper insights into the genetic control of
energy metabolism are warranted in order to improve long-term
compliance to prevention programs or therapeutic interventions.
Recently, genes with known psychophysiological functions have
gained much attention in the field of obesity and a common
pathophysiology have been suggested between depression, obesity
and related metabolic disorders [5–7]. The neurotransmitters,
serotonin, noradrenaline and dopamine are important in the
central nervous system regulation of many physiological processes
including energy and glucose homeostasis [8–10]. Consequently,
these neural pathways are interesting targets for anti-obesity drugs,
antidepressants and agents for treatment of various eating
disorders [10–12]. However, major drug-induced adverse events
include body weight gain in treatment of psychiatric disorders
[10,13] and mood disorders in anti-obesity agents [14]. The large
intra- and inter-individual variability in clinical response to
antipsychotic drugs and their side effects is further linked to
genetic susceptibility [10,11,13]. Pharmacogenetic research focus-
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response by utilizing a candidate-gene approach [10,11], although
supporting evidence for a role of these genes in development of
obesity and associated metabolic traits from population-based
observational studies is sparse.
A plethora of studies indicates that serotonin (5-hydroxytrypta-
mine; 5HT) receptor 2A (5HT2A) and 2C (5HT2C) are involved
in the regulation of appetite and energy homeostasis [15],
although with functional differences between the genes [16].
Thus, 5HT2C -759C/T is shown to affect treatment-induced
weight gain in schizophrenic patients [17], and 5HT2A –1438G/A
has been linked to several neuro-psychiatric disorders [18–20] and
to abdominal obesity [21,22]. Transcripts of the serotonin receptor
have been found in the hypothalamus, including in the para-
ventricular nucleus, lesions of which result in obesity [23].
Catechol-O-methyltransferase (COMT) encodes for the COMT
enzyme responsible for the degradation of the catecholamines,
dopamine adrenaline and noradrenaline through both central and
peripheral effects [24,25]. There is evidence that changes in the
activity of COMT affect sympathetic tone, regulate the amounts of
active dopamine and noradrenaline in various cerebral regions and
thus is involved in multiple reward-motivated behaviour such as
obesity [10,11,24,25], mood and other mental processes [11,26].
Several polymorphisms of COMT have been described, but
24938A/G (rs4680) is the most extensively studied [26] showing
associations with schizophrenia, alcoholism and obesity [27].
In the present study, we examined 5HT2A –1438G/A (rs6311),
5HT2C -759C/T (rs3813929) and COMT 24938 A/G (rs4680) in
relation to obesity and related metabolic quantitative traits in a
group of middle-aged men representing a very broad range of BMI.
Methods
Study population
Among 362 200 Caucasian men examined at the mean age of
20 years at the draft boards in Copenhagen and its surroundings
during 1943–77, a randomly selected group of one in every
hundred men (n=3 601) and all obese men (n=1 930) were
manually identified. Obesity was defined as 35% overweight
relative to a local standard in use at the time, and this corresponds
to a BMI$31.0 kg/m
2, which proved to be above the 99th
percentile. All obese and half of the random sample, still living in
the region, were invited to a follow-up survey in 1992–94 at the
mean age of 46 years (survey S-46) and in 1998–2000 at the mean
age of 49 years (survey S-49). The criteria for invitation to the
follow-up surveys and the participation have been described
previously [28–30], and the number of participants shows the
expected attrition over time (Table 1). Phenotypic assessments
were carried out at both surveys, though much more thoroughly at
the second survey (S-49), and DNA was extracted from blood
sample buffy coats at the S-46. In total, 1 557 (726 obese and 831
randomly selected) participants were genotyped for the present
study, indicating that the randomly selected group represent 166
200 men originally identified at the draft board examination.
Among these 485 (209 obese and 276 randomly selected) had been
assessed in S-49.
We certify that all applicable institutional and governmental
regulations concerning the ethical use of human volunteers were
followed during this research. The Danish Data Protection Agency
and the regional Ethical Committee approved the study to be in
accordance with the Helsinki Declaration II. All participants
signed a written consent before participating.
Phenotypic measurement
Waist circumference (cm) was measured according to the WHO
recommendations [31] to the nearest 0.5 cm with the subjects
standing, using a nonexpendable linen tape measure,. Total body
fat mass (kg) was assessed by bioimpedance at S-46 and from the
DEXA scan at S-49. Fat body mass index (fat-BMI; kg/m
2) was
calculated as total body fat mass (kg) divided by height (m)
squared.
Participants in S-46 had non-fasting glucose and lipid levels
determined on fresh plasma samples. In the S-49 cohort, an oral
glucose tolerance test (OGTT) was conducted, except in
individuals with diagnosed and therefore likely treated diabetes
(n=10) [28]. Classification of IGT or T2D was done according to
the WHO diagnostic criteria [32]. Insulin sensitivity and acute
insulin response were assessed by the recently recommended
BIGTT indices (BIGTT-SI and BIGTT-AIR, respectively) on the
basis of measurements of plasma glucose and serum insulin at the
time points 0, 30 and 120 minutes during the OGTT [33]. Details
on data collections and measurement of anthropometric and other
phenotypic estimates have been described elsewhere [28,34,35].
Molecular genetic analyses
Genotyping of 5HT2A -1438G/A (rs6311), 5HT2C -759C/T
(rs3813929), and COMT 24938A/G (rs4680) was performed using
Table 1. Genotype distribution (%) and minor allele frequencies for the examined genes and SNPs in obese and controls
participants.
Survey Gene
Chromosomal
location dbSNP SNP
1 Obese Controls
Genotype MAF Genotype MAF
Wt He Ho Wt He Ho
S-46 5HT2A 13q14-q21 Rs6311 G/A 249 (34.6) 375 (52.4) 93 (13.0) 0.39 320 (38.8) 378 (46.0) 125 (15.2) 0.38
5HT2C Xq24 Rs3813929 C/T 613 (84.5) 2 113 (15.5) 0.16 695 (83.7) 2 136 (16.3) 0.16
COMT 22q11.21–q11.23 Rs4680 A/G 237 (33.0) 335 (46.7) 146 (20.3) 0.43 265 (32.4) 397 (48.6) 154 (19.0) 0.43
S-49 5HT2A 13q14–q21 Rs6311 G/A 70 (34.2) 111 (54.1) 24 (11.7) 0.39 107 (39.2) 125 (45.8) 41 (15.0) 0.40
5HT2C Xq24 Rs3813929 C/T 175 (83.7) 2 34 (16.3) 0.16 237 (85.9) 2 39 (14.1) 0.14
COMT 22q11.21–q11.23 Rs4680 A/G 64 (31.4) 103 (50.5) 37 (18.1) 0.43 80 (29.5) 142 (52.4) 49 (18.1) 0.44
1The minor alleles are shown in bold-faced letters. SNPs=single nucleotide polymorphisms, Wt=wild type, He=heterozygote, Ho=homozygote, MAF=minor allele
frequency.
doi:10.1371/journal.pone.0006696.t001
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type data were obtained in 96.7–98.7% of the DNA samples with
a genotype error rate of 0.0%.
Statistics
A likelihood ratio test for an additive, a dominant and a
recessive effect of the genotyped SNPs determined that a dominant
genetic model was chosen for 5HT2A rs6311 and (wild type versus
heterozygous and homozygous genotype), and a recessive genetic
model was chosen for the present analyses of COMT rs4680 (wild
type and heterozygous genotype versus homozygous genotype).
The 5HT2C receptor gene is located at the X chromosome, and
therefore the men in the present study had either one C- or T-
allele.
In order to properly take into account and optimally utilise the
strength of the sampling design, the two groups of obese and
controls have been analysed together at each follow-up survey S-
46 and S-49. The massive enrichment of the right tail of the BMI
distribution implies that the data cannot be analysed with BMI or
BMI-associated outcomes as response variables in common
regression models. Using a dichotomized case-control approach
would waste considerable statistical efficiency otherwise gained by
using the quantitative phenotypes. Limiting the analyses to obese
and control groups would also be a waste of the efficiency that is
implicit in the sampling design and would disregard the point in
having a sampling from a study population of 166,200 subjects at
S-46 and 55,200 subjects at S-49. The greater statistical power of
the wide coverage of the quantitative phenotypes was gained by
reversing the statistical models for the associations, i.e. estimation
of the odds of carrying the particular risk-allele genotype for a
given level of the phenotypes. This can be done without
distributional assumptions about the phenotypes. Standard logistic
regression analysis was applied to assess the odds ratios (ORs) of
the genotype (response variable) in relation to the phenotypes
(covariates, harmonised as z-scores for obesity phenotypes) in the
combined case and control groups. The regression model includes
relevant phenotypic predictors of this response. Logistic regres-
sions have previously been applied to genetic association studies in
which alleles or genotypes are treated as dependent variables [36–
41]. All analyses were adjusted for age as a continuous variable. P-
values,0.05 were considered statistically significant. Implications
of multiple testing are addressed in the discussion. Analyses were
performed using SAS statistical procedures (version 9.1; SAS
Institute Inc, Cary, NC).
Results
The distribution of the genotypes was almost the same at S-46
and S-49 indicating that the attrition of the study groups by time
was not dependent on the genotype (Table 1). Hardy-Weinberg
equilibrium for each SNP was tested in controls and revealed no
significant departures.
BMI, fat-BMI and waist circumference
We estimated the ORs of the genotype (response variable) in
relation to the phenotypes (covariates). Results from logistic
regression analyses for obesity phenotypes are given in odds ratios
with 95% confidence intervals (CIs).
Results from the logistic regression analyses showed that neither
5HT2A –1438G/A nor 5HT2C –759C/T was significantly
associated with BMI, fat-BMI or waist circumference (Table 2).
The COMT 24938A/G was associated with fat-BMI at S-46,
where a two-unit increase in fat-BMI increased the odds for the
GG-genotype by 8% (OR=1.08, CI=1.01–1.16, p=0.03).
COMT 24938A/G was associated with waist circumference at S-
46 with borderline significance, where an increment of five cm in
waist circumference increased the odds for the GG-genotype by
4% (OR=1.04, CI=1.00–1.09, p=0.06).
Metabolic traits
There were several statistically significant associations between
the examined SNPs and some of the metabolic traits. 5HT2A –
1438G/A was associated with serum cholesterol at S-46, where a
one-unit (10 mmol/L) increase in cholesterol increased the odds
for the minor A-allele 2.7 fold (OR=2.66, CI=1.11–6.40,
p=0.03), and an almost similar estimate was seen at S-49, albeit
not significant (Table 3). 5HT2C –759C/T was associated with
non-fasting plasma glucose at S-49, for which a one-unit
(10 mmol/L) increase in glucose increased the odds for the TT-
genotype 4.6 fold (OR=4.56, CI=1.13–18.4, p=0.03). Likewise,
Table 2. Odds ratio (OR) including 95% confidence intervals (CI) for 5HT2A rs6311 (dominant effect of the A allele, AA & AG vs GG),
5HT2C rs3813929 (effect of the T vs C alleles) and COMT rs4680 (recessive effect of the G allele, GG vs GA & AA) in relation to obesity
phenotypes.
5HT2A 5HT2C COMT
-1438G/A -759C/T 24938A/G
Obesity phenotypes OR (95% CI) P OR (95% CI) P OR (95% CI) P
S-46 (n=1570)
BMI (kg/m
2)
1 1.01 [0.97; 1.04] 0.70 1.02 [0.97; 1.07] 0.40 1.03 [0.99;1.08] 0.13
Fat-BMI (kg/m
2)
1 0.99 [0.93; 1.05] 0.73 1.04 [0.96; 1.12] 0.31 1.08 [1.01; 1.16] 0.03
Waist (cm)
2 1.00 [0.97; 1.04] 0.81 1.03 [0.98; 1.07] 0.29 1.04 [1.00; 1.09] 0.06
S-49* (n=551)
BMI (kg/m
2)
1 1.00 [0.95; 1.06] 0.99 1.03 [0.96; 1.11] 0.41 1.03 [0.96; 1.10] 0.47
Fat-BMI (kg/m
2)
1 1.01 [0.93; 1.10] 0.82 1.07 [0.95; 1.20] 0.25 1.04 [0.94; 1.16] 0.43
Waist (cm)
2 1.01 [0.95; 1.03] 0.80 1.04 [0.97; 1.12] 0.26 1.02 [0.95; 1.09] 0.55
BMI=body mass index, fat-BMI=fat body mass index.
1Per two-unit increment of BMI or fat-BMI.
2Per five cm increment of waist circumference.
doi:10.1371/journal.pone.0006696.t002
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for the TT-genotype by 35% (OR=0.65, CI=0.44–0.94,
p=0.02). COMT 24938A/G was associated with plasma glucose
levels at S-46 where an increment of a one-unit (10 mmol/L)
glucose increased the odds for the GG-genotype by 4%
(OR=1.04, CI=1.00–1.09, p=0.05; Table 3). The significant
associations for plasma glucose and acute insulin response seemed
to persist when adjusted for fat-BMI (data not shown). No
significant associations were observed with the other examined
metabolic traits.
IGT and T2D
Based on the above findings on glucose homeostasis, we
examined 5HT2C –759C/T and COMT 24938A/G in relation
to IGT and T2D. The 5HT2A –1438G/A did not associate with
glucose homeostasis, and therefore associations with IGT or T2D
were not examined. Results from logistic regression analyses in
162 subjects with IGT or T2D and 308 glucose-tolerant subjects
showed corresponding notable estimates, although of borderline
significance. Subjects with IGT or T2D had a trend to increase the
odds for the T-genotype for 5HT2C and GG-genotype for COMT
24938A/G by 53% (OR=1.53, CI=0.90–2.61, p=0.12) and
48% (OR=1.48, CI=0.91–2.41, p=0.12), respectively compared
to glucose-tolerant subjects (Table 4). Adjustment for fat-BMI did
not influence the estimates notably.
In total, 46.5% of the subjects with the T-genotype of 5HT2C –
759C/T had IGT or T2D, whereas only 34.2% subjects with the
C-genotype had IGT or T2D (x
2: p=0.05), implying a 12.3%
increased frequency of the T-allele in the presence of IGT or T2D
compared with glucose tolerant subjects (Figure 1A). COMT
24838A/G was also associated with IGT and T2D. In total,
41.9% of the subjects with the GG-genotype had IGT or T2D,
whereas only 30.3% subjects with the AA genotype had IGT or
T2D (x
2: p=0.06), implying 11.6% increased frequency of the
GG-genotype, in the presence of IGT or T2D (Figure 1B).
Combined effect of 5HT2C and COMT
Based on the present findings on glucose homeostasis, IGT and
T2D for 5HT2C and COMT, we examined the combined
genotype association of the minor risk genotypes of 5HT2C and
COMT in relation to obesity and related metabolic traits. In total,
58 (4.7%) subjects were carriers of both 5HT2C –759T and GG-
genotype of COMT 24938A/G. Analysis of the combined
genotype has been conducted only in S-46, because of a low
number of carriers in S-49 (n=12).
Table 4. Odds ratio (OR) including 95% confidence intervals
(CI) for 5HT2C rs3813929 (effect of the T vs C alleles) and COMT
rs4680 (recessive effect of the G allele, GG vs GA & AA) in
relation to IGT and T2D compared to glucose-tolerant
subjects before and after adjustment for fat-BMI (kg/m
2).
5HT2C COMT
-759C/T 24938A/G
IGT and T2D OR (95% CI) P OR (95% CI) P
S-49 (n=451)
Unadjusted 1.53 [0.90; 2.61] 0.12 1.48 [0.91; 2.41] 0.12
Adjusted for fat-BMI 1.50 [0.83; 2.71] 0.18 1.45 [0.83; 2.55] 0.19
IGT=impaired glucose tolerance, T2D=type 2 diabetes, fat-BMI=fat body mass
index.
doi:10.1371/journal.pone.0006696.t004
Table 3. Odds ratio (OR) including 95% confidence intervals (CI) for 5HT2A rs6311 (dominant effect of the A allele, AA & AG vs GG),
5HT2C rs3813929 (effect of the T vs C alleles) and COMT rs4680 (recessive effect of the G allele, GG vs GA & AA) in relation to
metabolic quantitative traits.
5HT2A 5HT2C COMT
-1438G/A -759C/T 24938A/G
Metabolic traits OR (95% CI) P OR (95% CI) P OR (95% CI) P
S-46 (n=1570)
p-glucose (10 mmol/L) 0.98 [0.94; 1.02] 0.38 1.01 [0.96; 1.07] 0.61 1.04 [1.00; 1.09] 0.05
s-Cholesterol (10 mmol/L) 2.66 [1.11; 6.40] 0.03 1.64 [0.54; 4.98] 0.38 1.23 [0.44; 3.49] 0.69
s-HDL (mmol/L) 0.88 [0.66; 1.16] 0.36 0.86 [0.59; 1.25] 0.43 0.79 [0.56; 1.12] 0.18
Systolic BP (10 mmHg) 0.97 [0.91; 1.03] 0.31 1.00 [0.92; 1.08] 0.93 0.98 [0.90; 1.05] 0.48
S-49 (n=551)
1
p-glucose (10 mmol/L) 1.74 [0.50; 6.09] 0.38 4.56 [1.13; 18.4] 0.03 0.75 [0.13; 4.32] 0.75
p-insulin (50 pmol/L) 1.13 [0.91; 1.39] 0.27 0.73 [0.51; 1.06] 0.10 1.05 [0.81; 1.37] 0.72
BIGTT-SI 0.94 [0.77; 1.15] 0.55 0.94 [0.72; 1.22] 0.64 0.89 [0.69; 1.14] 0.36
BIGTT-AIR 0.98 [0.74; 1.30] 0.88 0.65 [0.44; 0.94] 0.02 1.22 [0.83; 1.78] 0.31
s-Cholesterol (10 mmol/L) 3.29 [0.56; 19.5] 0.19 0.97 [0.10; 10.9] 0.98 0.19 [0.02; 1.94] 0.16
s-Triglycerides (mmol/L) 0.91 [0.77; 1.08] 0.29 1.17 [0.98; 1.39] 0.08 1.01 [0.83; 1.23] 0.93
s-HDL (mmol/L) 1.13 [0.59; 2.16] 0.73 1.32 [0.54; 3.19] 0.54 0.74 [0.32; 1.72] 0.49
s-FFA (mmol/L) 0.96 [0.30; 3.08] 0.95 2.37 [0.49; 11.4] 0.28 1.06 [0.24; 4.74] 0.94
Systolic BP (10 mmHg) 1.02 [0.91; 1.14] 0.73 1.04 [0.91; 1.20] 0.56 0.92 [0.80; 1.06] 0.22
BP=blood pressure, BIGTT-SI=OGTT-derived index of insulin sensitivity, BIGTT-AIR=OGTT-derived index of acute insulin response, FFA=free fatty acids.
1All values for the S-49 are derived from the OGTT examination and are therefore fasting compared with non-fasting for S-46.
doi:10.1371/journal.pone.0006696.t003
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combined risk genotype, all obesity phenotypes and total serum
cholesterol. A two-unit increase in BMI was associated with
increased odds for being carrier of the combined genotype by 12%
(OR=1.12, CI=1.03–1.21, p=0.006) (Table 5). Likewise a
two-unit increase in fat-BMI increased the odds for being carrier
of the combined genotype by 22% (OR=1.22, CI=1.08–1.38,
p=0.002). Each increment of five cm in waist circumference
increased the odds for being carrier of the combined genotype by
13% (OR=1.13, CI=1.04–1.22, p=0.003). Lastly, a one-unit
(10 mmol/L) increase in total serum cholesterol increased the odds
for being carrier of the combined genotype 5.6 fold (OR=5.60,
CI=0.99–31.4, p=0.05). Adjustment for fat-BMI showed that the
associations between the combined risk genotype, BMI, waist
circumference and total serum cholesterol were in part explained
by an effect of fat-BMI.
Carriers of the combined risk genotype were also associated
with IGT or T2D, where 66.7% of the carriers had IGT or T2D
compared with only 32.6% in non-carriers (x
2: p=0.01)
(Figure 1C).
Discussion
The present study revealed that the examined SNPs of 5HT2A
and 5HT2C did not associate with obesity, but COMT 24938A/G
was associated with fat-BMI. Associations were observed between
the examined SNPs, glucose homeostasis, serum cholesterol level
and a surrogate measure of acute insulin response. Combined
Figure 1. Frequency of IGT or T2D according to 5HT2C –759C/T, COMT 24938A/G and combined genotype analysis in the combined
group of obese and randomly selected men. Values are given as percentages. A: Frequency of IGT or T2D according to 5HT2C –759C/T. B:
Frequency of IGT or T2D according to COMT 24938A/G. C: Frequency of IGT or T2D according to combination of 5HT2C –759C/T T-allele and COMT
24938A/G GG-genotype. A: P-value for x
2=0.05, B: P-value for x
2=0.06, C: P-value for x
2=0.01.
doi:10.1371/journal.pone.0006696.g001
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revealed associations in relation to BMI, fat-BMI, waist circum-
ference and serum cholesterol levels, and were partly explained by
a possible mediating effects of fat-BMI. 5HT2C –759T and the
GG-genotype for COMT 24938A/G showed an increased
frequency in subjects with IGT or T2D. The combined genotype
analyses accentuated these effects and showed that carriers of the
combined risk genotype had increased frequency of IGT or T2D.
The present results have not been replicated and, given the
experience of complex trait genetics, warrant caution in
interpretation.
The present population-based cohort study of Danish Cauca-
sian men where the controls were randomly selected from the
same population in which the cases were identified effectively
prevents population stratification. The availability of several
repetitive measurements in the same individuals have given the
unique opportunity of analyzing and comparing a panel of specific
obesity-related phenotypes covering BMI, fat-BMI, waist circum-
ference and metabolic traits at two different ages. The samples
may seem small for a genetic association study; however, this
apparent limitation of the study is counteracted by the fact that the
control group represents approximately 200 times the size of the
randomly selected control group originally identified at the draft
board examination. The obese participants therefore were
representing the most extreme range of the obesity-related
phenotypes in this population at both surveys except for the
possible effects of differential attrition of the population during the
follow-up. The statistical efficiency of the current sampling design,
when analyzed as dichotomized case-control studies, corresponds
to about half what would be achieved by investigating the full
cohort. Keeping the phenotypes as quantitative variables in the
analyses, the efficiency is considerably higher as reflected in the
fairly narrow CIs, which means that we thereby have narrowed
down the likely true OR’s that could have given rise to the
observed ORs. Thus, owing to the sampling design of the obese
participants with massive enrichment of the right tail of the BMI
distribution it is possible to demonstrate stronger associations in
our cohort compared to already published studies examining
obesity-related genotype-phenotype associations.
By nature, our findings are exploratory, and the significant P-
values were therefore not corrected for multiple hypotheses testing.
Estimating the false discovery rate by the method of Benjamini
and Hochberg [42], the adjusted P-value for 68 dependent tests
would be 0.011, which implies that all significant associations,
except for the combined genotype analyses in relation to obesity,
would be false-positive. None of the exploratory results would
reach the enhanced significance criterion under application of the
conservative Bonferroni correction for an overall type I error rate
of 0.05 (one false-positive per 20 tests), which would result in a
significance threshold of 0.0007. The examined phenotypes may
be inter-correlated to various extents, but according to a recent
twin study [43], there is little common underlying genetic or
shared environmental aetiology behind these correlations, which
justifies the separate analysis of each of the phenotypes in the
present study.
Although, we have avoided sex-related confounding, which
otherwise may have an impact on the genetic variation of body
composition, the results suggest that also the role of the gene
variants should be examined in women. The –759T allele is
functional and has been associated with increased promoter
activity compared with the wild type –759C allele [5]. There is
indication of sex-related effects and one study has reported higher
frequency of the C-allele in obese women, which was associated
with weight loss resistance in heterozygote women suggesting that
women are more prone to serotonin-induced weight changes [44].
Only one recently published study has examined the effect of –
759C/T of the 5HT2C receptor gene on obesity and T2D in a
population-based study design [45]. Results from the study of 315
Greek men and women showed a positive association between
5HT2C rs3813929 and T2D, but not with BMI. However, in the
same study, the 5HT2C –759T allele frequency was 10.7% lower
in diabetic individuals compared to glucose tolerant individuals,
which is in discordance with our finding of a 12% increased
frequency of the T-allele in men with IGT or T2D (accentuated by
combined genotype analysis). The present discrepancy may be
ascribed to a high mean age of the Greek subjects and a small
study population not enriched on obesity.
COMT has been studied intensively in relation to several
reward-motivated behaviours such as development of diet-induced
obesity [27,46]. It is known that the G-allele of COMT rs4680 is
associated with low COMT activity of soluble COMT, thus
conferring slow detoxification of neurotransmitters [47] such as
the degradation and inactivation of dopamine [26,46]. We found
an association between COMT 24938A/G and fat-BMI, and
borderline with waist circumference, which is in accordance with
the suggested role of COMT polymorphisms in obesity [24,27,48]
and in line with results from a recently published population-based
study showing an association between COMT 24938A/G and
body fat distribution measured as waist-hip ratio [48]. In a recent
randomized controlled trial, no association between COMT
24938A/G and obesity was observed, yet a significant association
between a different COMT SNP (rs4818) and BMI was reported
[27]. However, because COMT is affecting both the degradation
of noradrenaline and dopamine, a decreased activity of the gene
product will enhance the post-receptor effects of these neuro-
transmitters. In this context, it is interesting that re-uptake
inhibition on these two systems, that will tend to have the same
effect, is an effective way to produce a weight loss in humans
[12,25].
Table 5. Combined genotype analyses. Odds ratio (OR)
including 95% confidence intervals (CI) for 5HT2C T-allele
(rs3813929) and COMT GG-genotype (rs4680) in relation to
metabolic quantitative traits before and after adjustment for
fat-BMI (kg/m
2).
5HT2C –759T COMT 24938G/G
Unadjusted
Adjusted for
fat-BMI
Obesity phenotypes OR (95% CI) P OR (95% CI) P
S-46 (n=1570)
BMI (kg/m
2)
1 1.12 [1.03; 1.21] 0.006 1.01 [0.61; 1.69] 0.96
Fat-BMI (kg/m
2)
1 1.22 [1.08; 1.38] 0.002 22
Waist (cm)
2 1.13 [1.04; 1.22] 0.003 1.13 [0.87; 1.45] 0.36
Metabolic traits
p-glucose (10 mmol/L) 1.06 [0.98; 1.14] 0.15 22
s-Cholesterol (10 mmol/L) 5.60 [0.99; 31.4] 0.05 4.90 [0.82; 29.2] 0.08
s-HDL (mmol/L) 0.76 [0.37; 1.56] 0.45 22
Systolic BP (10 mmHg) 1.09 [0.94; 1.26] 0.24 22
BMI=body mass index, fat-BMI=fat body mass index, BP=blood pressure.
p-=plasma, s-=serum.
1Per two-unit increment of BMI or fat-BMI.
2Per five cm increment of waist circumference.
doi:10.1371/journal.pone.0006696.t005
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noradrenaline and dopamine pathways in energy homeostasis and
hence as targets for development of effective anti-obesity agents
[8,49,50], we did not detect associations of significant importance
with obesity. At first step, our results suggested that 5HT2C –
759C/T and COMT 29438A/G is associated with IGT and T2D,
but partly independent of obesity. However, our results also
implied that the combined genotypes of 5HT2C –759C/T and
COMT 29438A/G may have an impact on obesity and thus, in this
way, on the development of IGT or T2D. The present and
potential discrepancies between studies underline the continuing
challenges of studies with different populations with different
characteristics and pathophysiological and life-style related
characteristics that may modify the effects of the examined gene
variants.
Our findings lend further support to the involvement of
serotonin, noradrenaline and dopamine in energy and glucose
homeostasis, and hence on the risk of obesity and T2D, in
particular when combined genotype associations are explored.
The results underscore the need for additional research in order to
replicate the results and to identify the complex interplay between
the examined psychophysiological genes that may further
characterize their functionality in energy homeostasis.
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